Session » Vasculitis – ANCA-Associated Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1610

Anti-neutrophil Cytoplasmic Antibodies Associated Interstitial Pneumonia: A New Clinical Entity?

10:30AM-12:30PM: Abstract Number: 1603

Antineutrophil Cytoplasmic Autoantibody Levels in Patients in the Avacopan Phase 3 Trial

10:30AM-12:30PM: Abstract Number: 1597

Baseline Glucocorticoid-Related Toxicity in Newly-Diagnosed and Relapsing ANCA-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 1601

Changing Spectrum of Systemic Therapies for Eosinophilic Granulomatosis with Polyangiitis from 2006-2023

10:30AM-12:30PM: Abstract Number: 1609

Characteristics of a Cohort of Patients with Interstitial Lung Disease and ANCA Positivity in a University Hospital

10:30AM-12:30PM: Abstract Number: 1605

Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1602

Complications in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Patients: A Nationwide Analysis

10:30AM-12:30PM: Abstract Number: 1606

Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data

10:30AM-12:30PM: Abstract Number: 1596

Efficacy of Eosinophil-Targeting Therapies According to Disease Severity in Patients with Eosinophilic Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1593

Efficacy of Increasing the Dose of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1599

Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis with Poor-Prognosis Factors: A Target Trial Emulation Study

10:30AM-12:30PM: Abstract Number: 1600

Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis Without Poor-Prognosis Factors: A Target Trial Emulation Study

10:30AM-12:30PM: Abstract Number: 1611

Impact of Mepolizumab on Patient-reported Outcomes in Eosinophilic Granulomatosis with Polyangiitis by Using the ANCA-associated Vasculitis Patient-reported Outcomes (AAV-PRO) Questionnaire: A European Multicentre Prospective Study

10:30AM-12:30PM: Abstract Number: 1608

Interstitial Lung Disease in ANCA-associated Vasculitis: A Retrospective Study of Clinical Characteristics, Radiographic Features, and Outcomes

10:30AM-12:30PM: Abstract Number: 1607

Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

10:30AM-12:30PM: Abstract Number: 1592

Overlapping Forms of Eosinophilic Granulomatosis with Polyangiitis and Granulomatosis with Polyangiitis: Presentation, Management and Outcomes

10:30AM-12:30PM: Abstract Number: 1598

Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling

10:30AM-12:30PM: Abstract Number: 1594

Response to Mepolizumab Therapy in a Single-center Cohort of Eosinophilic Granulomatosis with Polyangiitis Patients: Characterization of Cytokine/Chemokine Pattern and Phenotypic Stratification

10:30AM-12:30PM: Abstract Number: 1595

Tezepelumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study

10:30AM-12:30PM: Abstract Number: 1604

Utilizing Machine Learning with Claims Data to Diagnose and Quantify the Prevalence of Eosinophilic Granulomatosis with Polyangiitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].